Merck KGaA, Darmstadt, Germany, has announced its plan to acquire U.S.-based biopharmaceutical company SpringWorks Therapeutics, Inc., in a deal valued at approximately $3.9 billion. This acquisition represents a major step in Merck’s strategy to accelerate the growth of its Healthcare business and reinforce its position in the rare tumor market.

The definitive agreement stipulates a purchase price of $47 per share in cash, reflecting a 26% premium over SpringWorks’ 20-day average share price prior to acquisition rumors. The transaction will bring immediate revenue contributions to Merck KGaA, Darmstadt, Germany, and is expected to be accretive to its earnings per share pre (EPS pre) by 2027.

Expanding Innovation in Rare Tumors

SpringWorks brings two first-in-class, FDA-approved therapies to Merck’s portfolio:

• OGSIVEO® (nirogacestat): The first systemic standard-of-care therapy for adults with progressing desmoid tumors requiring systemic treatment.
• GOMEKLI™ (mirdametinib): The first approved therapy for adults and children aged two years and older with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) not amenable to complete resection.

Both therapies are currently under regulatory review in Europe, with European Medicines Agency (EMA) decisions expected in 2025.

“We have the unique opportunity with SpringWorks to establish a leadership position in rare tumors and build a strong foundation for further investments in this area,” said Peter Guenter, CEO of Healthcare at Merck KGaA, Darmstadt, Germany.

The acquisition also complements Merck’s existing developments, including its recent worldwide commercialization rights acquisition for pimicotinib, an investigational therapy for tenosynovial giant cell tumor (TGCT).

Strategic Fit and Global Expansion

This acquisition aligns with Merck KGaA, Darmstadt, Germany’s broader M&A strategy, which emphasizes external innovation, early value creation, and expanding the company’s presence in the U.S. pharmaceutical market. SpringWorks’ focus on serious rare diseases and its promising pipeline perfectly match Merck’s ambition to deliver transformative treatments globally.

“The agreed acquisition of SpringWorks is a major step in our active portfolio strategy to position our company as a globally diversified, innovation and technology powerhouse,” said Belén Garijo, Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany.

Looking Ahead

Upon closing, expected in the second half of 2025 (pending customary approvals), SpringWorks will be integrated into Merck’s global Healthcare business. The move offers SpringWorks the opportunity to expand its footprint beyond the U.S., leveraging Merck’s worldwide infrastructure.

SpringWorks CEO, Saqib Islam, emphasized the shared values between the two companies, noting that the merger will “build a brighter future for the patient communities we seek to serve,” while providing “new opportunities for SpringWorks employees as part of a global organization.”

Merck KGaA, Darmstadt, Germany, continues to solidify its position as a leader in science and technology, operating across Life Science, Healthcare, and Electronics with more than 62,000 employees in 65 countries.

Cosmael ThinkLab Commentary:

This acquisition is a textbook example of strategic expansion: a focused bet on rare diseases where unmet needs are high, therapeutic innovation is advancing, and global distribution can deliver immediate value. Merck’s move not only strengthens its rare tumor portfolio but also significantly enhances its U.S. presence, positioning it for sustainable growth across healthcare markets worldwide.